Clinical Trials Using Anti-CD123/CD3 Monoclonal Antibody MGD006

Clinical trials are research studies that involve people. The clinical trials on this list are studying Anti-CD123/CD3 Monoclonal Antibody MGD006. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-4 of 4
  • Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia

    This phase I trial studies the side effects and best dose of flotetuzumab and how well it works in treating patients with acute myeloid leukemia that has come back (recurrent) or has not responded to treatment (refractory). Immunotherapy with flotetuzumab may induce changes in the body’s immune system and may interfere with the ability of leukemia cells to grow and spread. Giving flotetuzumab may stop the leukemia from growing or shrink for a period of time, as well as possibly lessening symptoms, such as pain, that are caused by the leukemia.
    Location: 19 locations

  • Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)

    The primary objective of this study now is to assess the anti-neoplastic activity of flotetuzumab in patients with PIF / ER AML, as determined by the proportion of patients who achieve complete remission (CR) or complete remission with partial hematologic recovery (CRh).
    Location: 14 locations

  • Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies

    This phase I trial studies the best dose and side effects of flotetuzumab for the treatment of patients with blood cancers (hematological malignancies) that have spread to other places in the body (advanced) and have come back after a period of improvement (relapsed) or does not respond to treatment (refractory). Flotetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread.
    Location: City of Hope Comprehensive Cancer Center, Duarte, California

  • Flotetuzumab for the treatment of Relapsed Acute Myeloid Leukemia (AML) Following Allogeneic Hematopoietic Cell Transplantation

    This phase II trial studies the effect of flotetuzumab in treating patients with acute myeloid leukemia that has come back (relapsed) following allogeneic hematopoietic cell transplantation. Flotetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread.
    Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri